logo

BCAB

Bioatla·NASDAQ
--
--(--)
--
--(--)
6.14 / 10
Outperform

BCAB's fundamentals score 6.1/10, earning an Outperform rating. Key strengths include a healthy interest-coverage ratio (EBIT/Interest expense = 15.48%), robust revenue growth (Operating revenue YoY +92.66%), and positive valuation spreads (Profit-MV = 0.46, Asset-MV = -0.50). The primary concern is Days sales outstanding at 72.55 days, which drags on working-capital efficiency. Overall, the company's financial health is solid, supporting a favorable fundamental view despite this one weakness.

Fundamental(6.14)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight17.04%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.46%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-1.87%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight13.59%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.60%
1M Return8.45%
PB-ROE
Value1.49
Score3/3
Weight18.43%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.36%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.56%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight25.20%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.36%
1M Return8.41%
Is BCAB undervalued or overvalued?
  • BCAB scores 6.14/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -0.22 P/E ratio, -0.43 P/B ratio, and 32.35% earnings growth, these metrics solidify its Outperform investment rating.